The influence of iron status and genetic polymorphisms in the HFE gene on the risk for postoperative complications after bariatric surgery: a prospective cohort study in 1,064 patients

Table 9 Comparison of HFE gene status with iron status.

	Hepatic Iron Staining		Serum Iron (ug/dL)			Ferritin (ng/mL)			Iron binding capacity (ug/dL)			Transferrin saturation (%)
	N with data	Iron staining (%)	N with data	Median [Q1, Q3]	Abnormal (% > 160)	N with data	Median [Q1, Q3]	Abnormal (% > 400)	N with data	Median [Q1, Q3]	Abnormal (% > 428)	N with data	Median [Q1, Q3]	Abnormal (% > 55)
C282Y
Normal/Hetero (N = 1061)	1061	182 (17%)	892	62 [50, 79]	5 (<1%)	898	99 [50, 167]	34 (4%)	893	316 [287, 349]	24 (3%)	889	20 [15, 25]	3 (<1%)
Homo (N = 3)	3	1 (33%)	2	106 [106, 106]	0 (0%)	2	306 [112, 500]	1 (50%)	2	316 [284, 349]	0 (0%)	2	34 [30, 37]	0 (0%)
p-value ^A		0.43		NA	0.99		NA	0.076		NA	0.99		NA	0.99
H63D
Normal/Hetero (N = 1034)	1034	178 (17%)	868	62 [49, 79]	5 (<1%)	872	99 [50, 167]	33 (4%)	869	316 [287, 349]	23 (3%)	865	20 [15, 25]	2 (<1%)
Homo (N = 30)	30	5 (17%)	26	63 [57, 67]	0 (0%)	28	86 [44, 171]	2 (7%)	26	316 [272, 348]	1 (4%)	26	21 [17, 24]	1 (33%)
p-value ^A		0.99		0.75	0.99		0.75	0.30		0.38	0.51		0.49	0.085
C282Y/H63D*
Allele dose <2 (N = 1011)	1011	172 (17%)	847	61 [49, 78]	3 (<1%)	851	99 [50, 167]	30 (4%)	848	317 [288, 349]	23 (3%)	844	19 [15, 25]	0 (0%)
Allele dose 2 + (N = 53)	53	11 (21%)	47	69 [59, 90]	2 (4%)	49	91 [49, 187]	5 (10%)	47	298 [272, 335]	1 (2%)	47	24 [19, 32]	3 (6%)
p-value ^A		0.46		0.0005	0.024		0.98	0.037		0.0073	0.99		<.0001	0.0001

*An allele dose of 2+ includes all patients that were Homozygous for C282Y, Homozygous for H63D, or Heterozygous for both C282Y and H63D.
A = p-values are resulted from Fisher's exact test and wilcoxon rank sum test

ISSN: 1754-9493